Therapeutic Innovation Australia Limited
About
Therapeutic Innovation Australia Limited (TIA) is an Australian not-for-profit company established in 2008, serving as the lead agent for a National Collaborative Research Infrastructure Strategy (NCRIS) project funded by the Australian Department of Education. Its core mission is to enable and accelerate the translation of research discoveries into new therapeutics by providing coordinated and accessible world-class research infrastructure facilities across Australia.
Tips for Applicants
Applicants for the Pipeline Accelerator program must provide at least 50% matching cash co-investment. Applications are submitted online, and it is strongly advised to draft the application on a provided template as the online form cannot be saved. Early career and/or female researchers are particularly encouraged to apply. Funding specifically covers costs associated with accessing TIA, Phenomics Australia, and optionally NDF and Bioplatforms Australia supported facilities.
Giving Philosophy
TIA aims to foster a vibrant and productive Australian Research and Development ecosystem by lowering the financial barriers for translational researchers, including academics, clinicians, medical research institutes, and small-to-medium enterprises (SMEs), to access critical expertise and services. They invest in infrastructure to support the therapeutic development pipeline, offering competitive voucher schemes and encouraging diversity, particularly among early career and female researchers.
Giving History
ACNC Financial History
| Year | Grants Given | Revenue | Total Assets | Net Assets |
|---|---|---|---|---|
| FY2023 | $6.5M | $9.4M | $10.8M | $2.0M |
| FY2022 | $10.5M | $13.1M | $10.6M | $1.6M |
| FY2021 | $9.9M | $12.4M | $12.4M | $1.4M |
| FY2020 | $7.0M | $8.5M | $11.1M | $1.3M |
| FY2019 | $5.7M | $6.7M | $11.8M | $756K |
| FY2018 | $3.2M | $4.0M | $1.2M | $416K |
| FY2017 | $3.8M | $4.6M | $1.1M | $261K |
| 7yr total | $46.6M | Source: ACNC Annual Information Statements | ||
Programs (from website)
Pipeline Accelerator
A competitive scheme providing a partial subsidy (up to 50% of total cost, capped at $50,000) to support experimental development activities for therapeutic discovery and development in Australia. It targets academics and Small-to-Medium Enterprises (SMEs) to facilitate access to NCRIS-supported research facilities.
Technical Feasibility Assessments
Offers $10,000 vouchers to access specific product development advice at Cell & Gene Therapy facilities.